178 related articles for article (PubMed ID: 29243576)
1. A Novel Polymer-Lipid Hybrid Nanoparticle for the Improvement of Topotecan Hydrochloride Physicochemical Properties.
Silva EJ; Souza LG; Silva LAD; Taveira SF; Guilger RC; Liao LM; Queiroz Junior LHK; Santana MJ; Marreto RN
Curr Drug Deliv; 2018; 15(7):979-986. PubMed ID: 29243576
[TBL] [Abstract][Full Text] [Related]
2. Development of topotecan loaded lipid nanoparticles for chemical stabilization and prolonged release.
Souza LG; Silva EJ; Martins AL; Mota MF; Braga RC; Lima EM; Valadares MC; Taveira SF; Marreto RN
Eur J Pharm Biopharm; 2011 Sep; 79(1):189-96. PubMed ID: 21352915
[TBL] [Abstract][Full Text] [Related]
3. Screening of lipid carriers and characterization of drug-polymer-lipid interactions for the rational design of polymer-lipid hybrid nanoparticles (PLN).
Li Y; Taulier N; Rauth AM; Wu XY
Pharm Res; 2006 Aug; 23(8):1877-87. PubMed ID: 16850265
[TBL] [Abstract][Full Text] [Related]
4. Molecular interactions, internal structure and drug release kinetics of rationally developed polymer-lipid hybrid nanoparticles.
Li Y; Wong HL; Shuhendler AJ; Rauth AM; Wu XY
J Control Release; 2008 May; 128(1):60-70. PubMed ID: 18406489
[TBL] [Abstract][Full Text] [Related]
5. Topotecan-loaded lipid nanoparticles as a viable tool for the topical treatment of skin cancers.
Venâncio JH; Andrade LM; Esteves NLS; Brito LB; Valadares MC; Oliveira GAR; Lima EM; Marreto RN; Gratieri T; Taveira SF
J Pharm Pharmacol; 2017 Oct; 69(10):1318-1326. PubMed ID: 28703281
[TBL] [Abstract][Full Text] [Related]
6. A novel core-shell lipid nanoparticle for improving oral administration of water soluble chemotherapeutic agents: inhibited intestinal hydrolysis and enhanced lymphatic absorption.
Wang T; Shen L; Zhang Z; Li H; Huang R; Zhang Y; Quan D
Drug Deliv; 2017 Nov; 24(1):1565-1573. PubMed ID: 29029577
[TBL] [Abstract][Full Text] [Related]
7. The role of pH and ring-opening hydrolysis kinetics on liposomal release of topotecan.
Fugit KD; Anderson BD
J Control Release; 2014 Jan; 174():88-97. PubMed ID: 24231406
[TBL] [Abstract][Full Text] [Related]
8. Revisiting the nanoformulation design approach for effective delivery of topotecan in its stable form: an appraisal of its in vitro Behavior and tumor amelioration potential.
Padhi S; Mirza MA; Verma D; Khuroo T; Panda AK; Talegaonkar S; Khar RK; Iqbal Z
Drug Deliv; 2016 Oct; 23(8):2827-2837. PubMed ID: 26548664
[TBL] [Abstract][Full Text] [Related]
9. Optimization of controlled release nanoparticle formulation of verapamil hydrochloride using artificial neural networks with genetic algorithm and response surface methodology.
Li Y; Abbaspour MR; Grootendorst PV; Rauth AM; Wu XY
Eur J Pharm Biopharm; 2015 Aug; 94():170-9. PubMed ID: 25986587
[TBL] [Abstract][Full Text] [Related]
10. Ion-Pairing Contribution to the Liposomal Transport of Topotecan as Revealed by Mechanistic Modeling.
Fugit KD; Anderson BD
J Pharm Sci; 2017 Apr; 106(4):1149-1161. PubMed ID: 28007561
[TBL] [Abstract][Full Text] [Related]
11. Factors affecting drug encapsulation and stability of lipid-polymer hybrid nanoparticles.
Cheow WS; Hadinoto K
Colloids Surf B Biointerfaces; 2011 Jul; 85(2):214-20. PubMed ID: 21439797
[TBL] [Abstract][Full Text] [Related]
12. Central composite rotatable design for optimization of budesonide-loaded cross-linked chitosan-dextran sulfate nanodispersion: characterization,
Bodas DS; Ige PP
Drug Dev Ind Pharm; 2019 Jul; 45(7):1193-1204. PubMed ID: 30983428
[TBL] [Abstract][Full Text] [Related]
13. Engineering of a hybrid polymer-lipid nanocarrier for the nasal delivery of tenofovir disoproxil fumarate: physicochemical, molecular, microstructural, and stability evaluation.
Pokharkar VB; Jolly MR; Kumbhar DD
Eur J Pharm Sci; 2015 Apr; 71():99-111. PubMed ID: 25708940
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo studies of different liposomes containing topotecan.
Hao YL; Deng YJ; Chen Y; Wang XM; Zhong HJ; Suo XB
Arch Pharm Res; 2005 May; 28(5):626-35. PubMed ID: 15974453
[TBL] [Abstract][Full Text] [Related]
15. Design of nanocarriers for nanoscale drug delivery to enhance cancer treatment using hybrid polymer and lipid building blocks.
Zhang RX; Ahmed T; Li LY; Li J; Abbasi AZ; Wu XY
Nanoscale; 2017 Jan; 9(4):1334-1355. PubMed ID: 27973629
[TBL] [Abstract][Full Text] [Related]
16. Long-Acting Efavirenz and HIV-1 Fusion Inhibitor Peptide Co-loaded Polymer-Lipid Hybrid Nanoparticles: Statistical Optimization, Cellular Uptake, and
Surve DH; Jirwankar YB; Dighe VD; Jindal AB
Mol Pharm; 2020 Oct; 17(10):3990-4003. PubMed ID: 32808785
[TBL] [Abstract][Full Text] [Related]
17. Development of a new delivery system consisting in "drug--in cyclodextrin--in nanostructured lipid carriers" for ketoprofen topical delivery.
Cirri M; Bragagni M; Mennini N; Mura P
Eur J Pharm Biopharm; 2012 Jan; 80(1):46-53. PubMed ID: 21839833
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of topotecan nanoparticles for intravitreal chemotherapy of retinoblastoma.
Delrish E; Jabbarvand M; Ghassemi F; Amoli FA; Atyabi F; Lashay A; Soleimani M; Aghajanpour L; Dinarvand R
Exp Eye Res; 2021 Mar; 204():108423. PubMed ID: 33453276
[TBL] [Abstract][Full Text] [Related]
19. Preparation and characterization of modified lipid nanoparticles for doxorubicin controlled release.
Ying XY; Du YZ; Chen WW; Yuan H; Hu FQ
Pharmazie; 2008 Dec; 63(12):878-82. PubMed ID: 19177903
[TBL] [Abstract][Full Text] [Related]
20. Baicalin-loaded PEGylated lipid nanoparticles: characterization, pharmacokinetics, and protective effects on acute myocardial ischemia in rats.
Zhang S; Wang J; Pan J
Drug Deliv; 2016 Nov; 23(9):3696-3703. PubMed ID: 27749105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
